Epizyme Inc  

(Public, NASDAQ:EPZM)   Watch this stock  
Find more results for EPZM
-0.25 (-1.44%)
After Hours: 17.10 0.00 (0.00%)
Feb 22, 4:48PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.95 - 17.65
52 week 9.30 - 20.45
Open 17.50
Vol / Avg. 0.00/471,215.00
Mkt cap 1.18B
P/E     -
Div/yield     -
EPS -2.27
Shares 69.28M
Beta 2.19
Inst. own 97%
Mar 12, 2018
Epizyme Inc at Cowen Health care Conference - 4:10PM EDT - Add to calendar
Mar 7, 2018
Q4 2017 Epizyme Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Feb 14, 2018
Epizyme Inc at Leerink Partners Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -1376.45%
Operating margin - -1396.60%
EBITD margin - -1376.76%
Return on average assets -57.35% -46.86%
Return on average equity -72.11% -59.38%
Employees 112 -
CDP Score - -


400 Technology Sq Ste 4
CAMBRIDGE, MA 02139-3584
United States - Map
+1-617-2295872 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

Officers and directors

David M. Mott Independent Chairman of the Board
Age: 51
Bio & Compensation  - Reuters
Robert B. Bazemore Jr. President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Susan E. Graf Chief Business Officer, Principal Financial Officer
Age: 44
Bio & Compensation  - Reuters
Matthew Ros Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Suzanne Fleming Senior Vice President - Finance, Principal Accounting Officer, Treasurer
Age: 56
Bio & Compensation  - Reuters
Kevin T. Conroy Director
Age: 51
Bio & Compensation  - Reuters
Andrew R. Allen M.D. Ph.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
Kenneth M. Bate Independent Director
Age: 66
Bio & Compensation  - Reuters
Carl S. Goldfischer M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Richard F. Pops Independent Director
Age: 55
Bio & Compensation  - Reuters